Company intelligence / Profile preview

SLS Partnering

New York, New York, United States

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Positive Phase 2 results for SLS009 in r/r AML meeting all primary endpoints; Phase 3 REGAL trial of GPS in AML ongoing with positive IDMC recommendation and final analysis anticipated by year-end 2025.

Therapeutic areas: Oncology
Modalities: Peptide immunotherapySmall molecule
Industry: Biotech

Partnerships

Merck & Co., Inc.GenFleet Therapeutics (Shanghai), Inc.3D Medicines

Beyond the preview

Go deeper on SLS Partnering.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLS Partnering.

Explore the full profile